Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference
20 12월 2010 - 10:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present at the 29th Annual
J.P. Morgan Healthcare Conference. Management will provide an
overview of the Company, including a commercial update for FOLOTYN®
(pralatrexate injection) in relapsed or refractory peripheral
T-cell lymphoma, as well as an update on the Company’s plans for
FOLOTYN in advanced non-small cell lung cancer.
The presentation will begin at 8:00 a.m. Pacific Time on
Wednesday, January 12, 2011. There will be a live webcast of the
presentation, which will be accessible through a link available on
the home page and investor relations section of the Allos website.
In addition, the webcast will be archived for 90 days.
About Allos Therapeutics
Allos is currently focused on the development and
commercialization of FOLOTYN® (pralatrexate injection), a folate
analogue metabolic inhibitor. FOLOTYN is the first and only drug
approved in the U.S. for the treatment of patients with relapsed or
refractory peripheral T-cell lymphoma. Allos is also developing
FOLOTYN in other hematologic malignancies and solid tumors. Allos
retains exclusive worldwide rights to FOLOTYN for all indications.
Allos is headquartered in Westminster, CO. For additional
information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain
forward-looking statements that involve significant risks and
uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2010 and in the Company's other
periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of these presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles